List view / Grid view
The resulting compounds, which can bind to spike proteins from the original coronavirus, could serve as a starting point for developing broad-spectrum treatments for COVID-19.
20 December 2022 | By Eurofins DiscoverX Corp.
In this webinar, we present an approach for building MOA-based, simple, ready-to-use GLP-1 and GLP-2 bioassays and discuss assay validation results from Eurofins BPT.
The study highlights that a monoclonal antibody that targets heroin is effective in blocking the psychoactive and lethal effects of drug abuse in mice.
In pre-clinical studies, the University of Florida has identified two drugs that reverse ADM, a process that precedes pancreatic cancer.
Although Cordyceps mushrooms are challenging to cultivate, researchers have shown that they can be grown on edible insects to exploit their strong therapeutic potential.
The Chinese National Medical Products Administration has approved a Phase Ib study of Everest Medicines' EVER001, for potential treatment of glomerular diseases.
A bioluminescence resonance energy transfer sensor has been developed to report changes in intracellular Ca2+ concentrations during screening.
Using screening techniques, researchers have identified the compound called AN15368 which works as an antiparasitic against Chagas disease.
Scientists have identified and synthesised a small molecule that could be a more accessible and affective alternative to an antibody that treats a wide range of cancers.
An in-silico reaction screening strategy could produce compounds potentially useful for novel drug development.
Researchers from the US have identified several new small molecules that can induce mitophagy in leukaemia cells.
Drug Target Review’s Ria Kakkad recently visited ELRIG and the British Pharmacological Society’s conference on New Modalities in Pharmacology and Drug Discovery which took place in London, UK. This article shares some of the key takeaways from the event.
Scientists have created a new imaging technique with graphene which generates clearer pictures of the structures of small molecules.
NRG is developing a pipeline of brain-penetrant small molecule inhibitors of the mitochondrial permeability transition pore (mPTP) with potential as first-in-class treatments for Parkinson's disease and motor neuron disease.
Using chemical genetic screening and pre-clinical model studies, researchers have discovered that inducing ubiquitin-mediated degradation of mutant EZH2 could provide a more effective treatment strategy for haematologic malignancies.
